Cochrane
Library

Cochrane Database of Systematic Reviews

Chlorpromazine versus metiapine for schizophrenia (Review)

Zare M, Bazrafshan A

Zare M, Bazrafshan A.
Chlorpromazine versus metiapine for schizophrenia.
Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD011655.
DOI: [10.1002/14651858.CD011655.pub2](https://doi.org/10.1002/14651858.CD011655.pub2).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	5
Figure 1.	6
Figure 2.	6
OBJECTIVES	6
METHODS	6
RESULTS	11
Figure 3.	12
Figure 4.	14
Figure 5.	15
DISCUSSION	16
AUTHORS' CONCLUSIONS	17
ACKNOWLEDGEMENTS	18
REFERENCES	19
CHARACTERISTICS OF STUDIES	21
DATA AND ANALYSES	25
Analysis 1.1. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 1 Global state: 1. Clinically important improvement (CGI, high = poor)).	27
Analysis 1.2. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 2 Global state: 2a. Overall: remaining symptomatic.	27
Analysis 1.3. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 3 Global state: 2b. Overall: mean endpoint score (NOSIE, high = poor).	27
Analysis 1.4. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 4 Adverse effects: 1. General: "severe reactions".	28
Analysis 1.5. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 5 Adverse effects: 2a. Specific: central nervous system - drowsiness.	28
Analysis 1.6. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 6 Adverse effects: 2b. Specific: hepatic - abnormal liver function test.	28
Analysis 1.7. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 7 Adverse effects: 2c. Specific: movement disorders.	29
Analysis 1.8. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 8 Adverse effects: 2d. Specific: others.	30
Analysis 1.9. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 9 Leaving the study.	30
Analysis 1.10. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 10 Service utilisation: staying in hospital.	31
ADDITIONAL TABLES	31
CONTRIBUTIONS OF AUTHORS	32
DECLARATIONS OF INTEREST	32
SOURCES OF SUPPORT	32
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	33
INDEX TERMS	33

[Intervention Review]

Chlorpromazine versus metiapine for schizophrenia

Morteza Zare¹, Azam Bazrafshan²

¹Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. ²Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Contact address: Azam Bazrafshan, Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. bazrafshan.a.83@gmail.com.

Editorial group: Cochrane Schizophrenia Group.

Publication status and date: New, published in Issue 3, 2017.

Citation: Zare M, Bazrafshan A. Chlorpromazine versus metiapine for schizophrenia. *Cochrane Database of Systematic Reviews* 2017, Issue 3. Art. No.: CD011655. DOI: [10.1002/14651858.CD011655.pub2](https://doi.org/10.1002/14651858.CD011655.pub2).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Chlorpromazine, a widely available and inexpensive antipsychotic drug, is considered the benchmark treatment for schizophrenia worldwide. Metiapine, a dibenzothiazepine derivative, has been reported to have potent antipsychotic characteristics. However, no evidence currently exists on the effectiveness of chlorpromazine in treatment of people with schizophrenia compared to metiapine, a newer antipsychotic.

Objectives

To compare the effect of chlorpromazine versus metiapine for the treatment of people with schizophrenia

Search methods

We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials in November 2015 and 2016.

Selection criteria

All randomised controlled trials (RCTs) focusing on chlorpromazine versus metiapine for adults with schizophrenia. We included trials meeting our selection criteria and reporting useable data.

Data collection and analysis

We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention-to-treat basis. For continuous data, we estimated the mean difference between groups and its 95% CI. We employed a random-effects model for analyses. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE.

Main results

We included three studies randomising 161 people with schizophrenia. Data were available for only two of our seven pre-stated main outcomes. Clinically important improvement in global state was measured using the Clinical Global Impression (CGI). There was no clear difference between chlorpromazine and metiapine groups (2 RCTs, $n = 120$, RR 1.11, 95% CI 0.84 to 1.47, *very low quality evidence*) and numbers of participants with parkinsonism at eight weeks were similar (2 RCTs, $n = 70$, RR 0.97, 95% CI 0.46 to 2.03, *very low quality evidence*). There were no useable data available for the other key outcomes of clinically important improvement in mental state, readmission due to relapse, satisfaction with treatment, aggressive or violent behaviour, or cost of care.

Authors' conclusions

Chlorpromazine has been the mainstay treatment for schizophrenia for decades, yet available evidence comparing this drug to metiapine fails to provide high-quality trial based data. However, the need to determine whether metiapine is more or less effective than chlorpromazine seems to be lacking in clinical relevance and future research on this comparison seems unlikely.

PLAIN LANGUAGE SUMMARY

Chlorpromazine versus metiapine for schizophrenia

The aim of this review was to find good quality evidence for comparing the efficacy of chlorpromazine versus metiapine for schizophrenia.

Background

Schizophrenia is a common disabling and enduring mental illness worldwide. People with schizophrenia often experience positive symptoms such as delusions and hallucinations, and negative symptoms such as apathy (lack of interest) and loss of emotion.

Antipsychotic medicines have been successful for treating the positive symptoms but the negative symptoms remain difficult to treat and usually do not respond to routine antipsychotics. In addition, antipsychotic medicines often have unpleasant side effects.

Chlorpromazine is a widely available and inexpensive antipsychotic introduced in the 1950s and considered the benchmark treatment for schizophrenia worldwide. Initial research indicated that chlorpromazine helped global improvement and was effective at preventing relapse compared with placebo (dummy treatment). However, some of chlorpromazine's side effects, particularly incidence of movement disorders, are reported as severe or debilitating. Metiapine is a relatively newer antipsychotic medicine, reporting to be effective at treating the symptoms of schizophrenia while causing fewer side effects. However, there is currently no good quality information concerning metiapine's effectiveness directly compared to chlorpromazine.

Searching for evidence

In November 2015, the Information Specialist of the Cochrane Schizophrenia group searched their specialised register for relevant clinical trials. The search identified four reports. We inspected these reports and found they referred to three trials, randomising people with schizophrenia to receive chlorpromazine or metiapine.

Main results

Our review now includes three studies with 161 participants. The studies revealed no real differences between chlorpromazine and metiapine for improvement in global state or incidence of parkinsonism (an umbrella term for symptoms such as tremor (shaking), bradykinesia (slow movement), rigidity (stiffness), and postural instability (difficulty in balancing)). No data were reported for our other main areas of interest: mental state, service use, satisfaction with treatment, behaviour or cost of care.

Conclusions

We cannot draw firm conclusions from the data provided. The number of studies and number of participants in each study is small, all studies are also short term. Therefore, we rated the reported evidence as very low quality. However, metiapine is not a highly prescribed or used antipsychotic medicine, so although our evidence is poor, it probably will remain the best available evidence as it is unlikely new trials comparing metiapine with chlorpromazine will be conducted in the future.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Chlorpromazine versus metiapine for schizophrenia

Chlorpromazine versus metiapine for schizophrenia

Patient or population: people with schizophrenia

Settings: hospital

Intervention: chlorpromazine

Comparison: metiapine

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chlorpromazine	Metiapine				
Global state: clinically important improvement Clinical Global Impression Follow-up: mean 5 weeks	600 per 1000	684 per 1000 (522 to 894)	RR 1.11 (0.84 to 1.47)	120 (2 studies)	⊕⊕⊕⊕ Very low 1,2,3	1 trial reported CGI at 4 weeks, and 1 trial reported CGI at 6 weeks' follow-up, both indicated no significant difference between the 2 drugs.
Mental state: clinically important improvement	No studies reported this outcome.					
Adverse effects. Specific: movement disorders - parkinsonism Follow-up: 8 weeks	168 per 1000	144 per 1000 (89 to 233)	RR 0.97 (0.46 to 2.03)	70 (2 studies)	⊕⊕⊕⊕ Very low 1,2,3	-
Service use: readmission due to relapse	No studies reported on these outcomes.					
Satisfaction of participant or care provider with treatment						
Behaviour: aggressive or violent behaviour						
Cost of care

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

- ¹ Risk of bias: serious (downgraded by 1 level): study had unclear risk of other biases as supported by a pharmaceutical company for drug supply.
- ² Risk of bias: serious (downgraded by 1 level): studies had unclear risk of bias for allocation concealment and blinding outcome assessment.
- ³ Imprecision: serious (downgraded by 1 level): total sample size was very small.

BACKGROUND

Description of the condition

Schizophrenia is considered a common disabling and enduring mental problem with a global lifetime prevalence of about 1% (Dickenson 2013; Tardy 2011). According to World Health Organization (WHO) reports, an estimated 24 million people are currently living with schizophrenia worldwide. Low- and middle-income countries account for the majority of those people diagnosed with schizophrenia with few gender disparities (WHO 2001). Schizophrenia appears among the WHO seven top leading causes of disability and loss of years of lives due to disability (Dold 2012).

Schizophrenia is often grouped by two broad categories of positive or negative symptoms. Positive symptoms represent changes in behaviour or thought including delusions, hallucinations, catatonic symptoms such as mannerisms and bizarre posturing (Carpenter 1994; Crow 1980). In contrast, negative symptoms often represent an absence or deficit of normal emotional responses that are typically observed in healthy people. These negative symptoms can include flattening and poverty of speech, social withdrawal, inability to find pleasure in activities normally considered pleasurable and a lack of drive (Elis 2013). Different medications have been used to reduce symptoms of schizophrenia although the negative symptoms remain difficult to treat and usually do not respond to routine antipsychotic treatments.

Description of the intervention

Chlorpromazine, a widely available and inexpensive antipsychotic drug, is considered one benchmark treatment for schizophrenia worldwide. Since its discovery in 1951, with an outstanding impact, chlorpromazine emerged as the second revolution in psychiatry (Grozier 1973). Despite the advent of many new antipsychotic and neuroleptic drugs, chlorpromazine remains one of the first-line treatments for schizophrenia cases in low-to-moderate income regions as well as high-income regions in the world and is listed among the essential drugs for schizophrenia treatment by the WHO (WHO 2011). India and South East Asia are areas in which chlorpromazine is the most commonly used treatment, rather than other antipsychotic drugs (Adams 2014).

Primary evidence of using chlorpromazine for schizophrenia has indicated that it improved clinical recovery progress, facilitated global improvements and was effective at preventing relapse in comparison with placebo (Adams 2014). While chlorpromazine is considered an inexpensive drug, some of chlorpromazine's adverse effects could be expensive when it comes to human suffering and cost of treatments. Therefore, it might be better to use a safer, costly drug if the latter is equally potent, but has fewer, less severe adverse effects.

Metiapine is among those antipsychotic drugs, introduced in the 1970s, reported to be effective for treating the symptoms of schizophrenia with less severe adverse effects than chlorpromazine. It was originally produced by a US company - Merrell-Dow. This company was merged into Marion Merrell Dow, then acquired to become Hoechst Marion Roussel and finally subsumed into the Sanofi company. We are unsure of whether this compound is licenced for clinical use anymore.

How the intervention might work

Chlorpromazine, one of the widely used typical antipsychotic drugs, is an aliphatic phenothiazine (2-chloro-10-(3-dimethylaminopropyl)phenothiazine, Figure 1; Figure 2). Chlorpromazine acts as a blocking agent on different postsynaptic receptors by blocking alpha 1 adrenergic, 5HT_{2A}, D₂ and D₁ receptors in the brain (Saha 2013). Chlorpromazine is classified as a low-potency typical antipsychotic drug. Previously it was used for treating people with both acute and chronic psychoses, including schizophrenia and the manic phase of bipolar disorder as well as amphetamine-induced psychoses. There is evidence that chlorpromazine increases a person's chances of experiencing acute movement disorders (parkinsonism, rigidity, tremor, fits, sleepiness and weakness). In addition, chlorpromazine causes other adverse effects such as eye opacities, jaundice, photosensitivity, dry mouth, constipation, hypotension, urinary retention and blurred vision (Adams 2014). Chlorpromazine is also a sedating medication, prone to cause a variety of movement problems and increased weight. Evidence suggests that chlorpromazine leads to several anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapyramidal adverse effects, but may also cause metabolic syndromes, and movement disorders (Saha 2013).

Figure 1. Chlorpromazine - structure.

Metiapine (2-methyl-11-(4-methyl-1-piperazinyl)dibenzo [b,f] [1,4]thiazepine, [Figure 2](#)), a dibenzothiazepine derivative, has been reported to have potent neuroleptic and antipsychotic characteristics in humans ([Gallant 1970](#)). Early evidence found metiapine's pharmacological properties in animals similar to those of other neuroleptic drugs ([Ketteler 1970](#)). Its reported

characteristics included reduced spontaneous motor activity, inhibition of social and aggressive activity, and cataleptoid postures. There were unusually wide differences between the doses that altered behavioural patterns and those that produced incapacitation alterations of motor function ([Gibson 1973](#)).

Figure 2. Metiapine structure.

Why it is important to do this review

Despite its well-documented adverse effects, chlorpromazine is likely to remain one of the most globally prescribed treatments for schizophrenia. It is unclear whether chlorpromazine's efficacy and potential performance leads to better results in direct comparison with other antipsychotic drugs such as metiapine. We are also unclear if metiapine is of any value, and, if of value, whether metiapine is a largely forgotten antipsychotic drug.

This review is one of a series of Cochrane Reviews that will build up an over-review investigating the effects of chlorpromazine ([Table 1](#)).

OBJECTIVES

To compare the effect of chlorpromazine versus metiapine for the treatment of people with schizophrenia

METHODS

Criteria for considering studies for this review

Types of studies

All relevant randomised controlled trials (RCTs). If a trial had been described as 'double blind' but implied randomisation, we would have included such a trial in a sensitivity analysis (see [Sensitivity analysis](#)). We excluded quasi-randomised studies, such as those allocating by alternate days of the week. If people had been given additional treatments within chlorpromazine versus metiapine, we would only have included the data if the adjunct treatment had been evenly distributed between groups and it was only the chlorpromazine versus metiapine that was randomised.

Types of participants

Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and

delusional disorder, again, by any means of diagnosis. If we had found a trial with a range of diagnoses, we would have only included if the majority of participants had schizophrenia.

To ensure that information was as relevant to the current care of people with schizophrenia as possible we tried to clearly highlight the current clinical state (acute, early post-acute, partial remission, remission) and the stage (prodromal, first episode, early illness, persistent), and whether the studies primarily focused on people with particular problems (e.g. negative symptoms, treatment-resistant illnesses).

Types of interventions

1. Chlorpromazine

Any dose, timing or means of administration.

2. Metiapine

Any dose, timing or means of administration.

Types of outcome measures

Where possible, we divided available outcomes into short term (less than six months), medium term (seven to 12 months) and long term (over one year).

Primary outcomes

1. Global state

1.1. Clinically important improvement in global state as defined by each study.

2. Mental state

2.1. Clinically important improvement in mental state as defined by each study.

3. Adverse events

3.1. Incidence of clinically important movement disorder as defined by each study.

Secondary outcomes

1. Global state

1.1. Mean scores for global state.

1.2. Relapse.

2. Mental state

2.1. General symptoms - prevalence or mean scores.

2.2. Specific symptoms - prevalence or mean scores.

2.2.1. Positive symptoms (delusions, hallucinations, disordered thinking).

2.2.2. Negative symptoms (avolition, poor self-care, blunted affect).

2.2.3. Mood - depression

3. Adverse effects

3.1. General - prevalence or mean scores.

3.2. Specific - prevalence or mean scores.

3.2.1. Deaths by suicide or natural causes.

3.2.2. Movement disorders (extrapyramidal adverse effects, specifically tardive dyskinesia and neuroleptic malignant syndrome).

3.2.3. Sedation.

3.2.4. Dry mouth.

3.2.5. Others - categorised by system.

4. Leaving the study

5. Behaviour

5.1. General behaviour - prevalence or mean scores.

5.2. Specific behaviour - prevalence or mean scores.

5.2.1. Social functioning.

5.2.2. Employment status during trial (employed/unemployed).

5.2.3. Occurrence of violent incidents (to self, others or property).

6. Service utilisation outcome

6.1. Days in hospital.

6.2. Readmission due to relapse.

7. Quality of life

7.1. Important or mean change in person's quality of life as defined by each study.

8. Satisfaction with care

8.1. Important or mean change in satisfaction of participant or care provider as defined by each study.

9. Cost of care

10. 'Summary of findings' table

We used the GRADE approach to interpret findings ([Schünemann 2011](#)) and used GRADE profiler ([GRADEpro](#)) to import data from Review Manager 5 ([RevMan 2014](#)) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.

1. Global state: clinically important improvement.
2. Mental state: clinically important improvement.
3. Adverse events: incidence of any adverse event - movement disorders (See [Differences between protocol and review](#)).
4. Service use: readmission due to relapse.
5. Satisfaction of participant or care provider with treatment.
6. Behaviour: aggressive or violent behaviour.

7. Cost of care.

Search methods for identification of studies

Electronic searches

1. *Cochrane Schizophrenia Group's Study-Based Register of Trials*

The information Specialist searched the Register on 20 November 2015 and 23 November 2016 using the following search strategy:

(*Chlorpromazine* AND *Metiapine*) in Intervention Field of STUDY

In such a study-based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics.

This register is compiled by systematic searches of major resources (including MEDLINE, Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed and registries of clinical trials) and their monthly updates, handsearches, grey literature and conference proceedings (see [Group's Module](#)). There is no language, date, document type or publication status limitations for inclusion of records into the register.

Searching other resources

1. Reference searching

We inspected references of all included studies for further relevant studies.

2. Personal contact

We did not need to contact the first author of any included study for information regarding unpublished trials.

Data collection and analysis

Selection of studies

One review author (MZ) independently inspected citations from the searches and identified relevant abstracts and the second review author (AB) independently reinspected a random 50% sample to ensure reliability. One review author (MZ) obtained and inspected full reports of the abstracts meeting the review criteria and the second review author (AB) reinspected a random 50% of the full reports to ensure reliable selection. Had it not been possible to resolve disagreement by discussion, we would have attempted to contact authors of studies for clarification.

Data extraction and management

1. Extraction

One review author (MZ) extracted data from all included studies. In addition, to ensure reliability, the second review author (AB) independently extracted data from a random sample of these studies, comprising 50% of the total. We extracted data presented only in graphs and figures whenever possible, but included only if both review authors independently had the same result. If studies had been multicentre, we would have extracted data relevant to each component centre separately.

2. Management

2.1. Forms

We extracted data onto standard, simple forms.

2.2. Scale-derived data

We included continuous data from rating scales only if:

1. the psychometric properties of the measuring instrument were described in a peer-reviewed journal ([Marshall 2000](#)); and
2. the measuring instrument was not written or modified by one of the trialists for that particular trial;
3. the instrument was a global assessment of an area of functioning and not subscores which are not, in themselves, validated or shown to be reliable. However, there are exceptions, we would have included subscores from mental state scales measuring positive and negative symptoms of schizophrenia (see [Differences between protocol and review](#)).

Ideally, the measuring instrument should either be a self-report or completed by an independent rater or relative (not the therapist). We realised that this was not often reported clearly, therefore, we noted if this was the case or not in 'Description of studies'.

2.3. Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. However, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if endpoint data were not available. Where relevant, we would have combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences (SMD) throughout ([Higgins 2011a](#)).

2.4. Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we intended to apply the following standards to relevant data.

We would have entered data from studies of at least 200 participants in the analysis irrespective of the following rules, because skewed data pose less of a problem in large studies. We also entered all useable change data as when continuous data are presented on a scale that included a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not.

For endpoint data from studies with fewer than 200 participants:

1. if a scale started from the finite number zero, we would have subtracted the lowest possible value from the mean, and divide this by the standard deviation (SD). If this value is lower than one, it strongly suggests a skew and such data would not be used. If this ratio is higher than one but below two, there is a suggestion of skew. We would have entered these data and tested whether their inclusion or exclusion had changed the results substantially. Finally, if the ratio is larger than two we

would have used these data, because skew is less likely (Altman 1996; Higgins 2011b);

2. if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (Kay 1986)), which could have values from 30 to 210), the calculation described above is modified to take the scale starting point into account. In these cases, skew is present if $2\text{ SD} > (S - S_{\min})$, where S is the mean score and ' $S_{\min}$ ' is the minimum score.

2.5. Common measure

To facilitate comparison between trials, we intended to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).

2.6. Conversion of continuous to binary

Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there was a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the PANSS (Kay 1986), this can be considered as a clinically significant response (Leucht 2005a; Leucht 2005b). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.

2.7. Direction of graphs

Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for chlorpromazine versus metiapine. Where keeping to this made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'not un-improved') we reported data where the left of the line indicated an unfavourable outcome and noted it in the relevant graphs.

Assessment of risk of bias in included studies

Both review authors worked independently to assess risk of bias using criteria described in the *Cochrane Handbook for Systemic Reviews of Interventions* (Higgins 2011c) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. We did not need to contact the authors of the studies to obtain further information.

Measures of treatment effect

1. Binary data

For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (Boissel 1999) than odds ratios and those odds ratios tend to be interpreted as RR by clinicians (Deeks 2000). The number needed to treat for an additional beneficial (NNTB) or harmful NNTH outcome statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (Hutton 2009). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks.

2. Continuous data

For continuous outcomes, we estimated MD between groups. We preferred not to calculate effect size measures (SMD). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments.

Unit of analysis issues

1. Cluster trials

Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997; Gulliford 1999).

If clustering had not been accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error and attempt to contact first authors of studies to obtain intraclass correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (Gulliford 1999). If clustering was incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC (design effect = $1 + (m - 1) \times \text{ICC}$) (Donner 2002). If the ICC is not reported in future trials, we will assume it to be 0.1 (Ukoumunne 1999).

If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies will be possible using the generic inverse variance technique.

2. Cross-over trials

A major concern of cross-over trials is the carry-over effect. This occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we only used data from the first phase of cross-over studies.

3. Studies with multiple treatment groups

Where a study involved more than two treatment arms, if relevant, we would have presented the additional treatment arms in comparisons. If data were binary, we would have simply added these and combined them within the two-by-two table. If data were continuous, we would have combined data following the formula in the *Cochrane Handbook for Systemic Reviews of Interventions* (Higgins 2011a). Where the additional treatment arms were not relevant, we did not use these data.

Dealing with missing data

1. Overall loss of credibility

At some degree of loss to follow-up, data must lose credibility (Xia 2009). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. However, if more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would have addressed this within the 'Summary of findings' table by downgrading quality. Finally, we also downgraded quality within the 'Summary of findings' table where loss was 25% to 50% in total.

2. Binary

In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis (ITT)); where studies did not use an ITT analysis, we presented completer only data.

3. Continuous

3.1. Attrition

In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we reproduced these.

3.2. Standard deviations

If SDs were not reported, we would have tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs available for group means, and either a 'P' value or 't' value available for differences in mean, we can calculate them according to the rules described in the *Cochrane Handbook for Systemic Reviews of Interventions* (Deeks 2011): when only the SE is reported, SDs are calculated by the formula $SD = SE \times \text{square root } (n)$. The *Cochrane Handbook for Systemic Reviews of Interventions* presents detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics (Deeks 2011). If these formulae did not apply, we can calculate the SDs according to a validated imputation method, which is based on the SDs of the other included studies (Furukawa 2006). Although some of these imputation strategies could introduce error, the alternative is to exclude a given study's outcome and thus to lose information. We did not impute any SDs, if we had we would have examined the validity of the imputations in a sensitivity analysis excluding imputed values.

3.3. Assumptions about participants who left the trials early or were lost to follow-up

Various methods are available to account for participants who left the trials early or are lost to follow-up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently, methods such as multiple imputation or mixed-effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (Leon 2006), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups are often the core problem in randomised trials of schizophrenia. Therefore, we did not exclude studies based on the

statistical approach used. However, we preferred to use the more sophisticated approaches (e.g. we preferred MMRM or multiple-imputation to LOCF and to only present completer analyses if some type of ITT data were not available at all). Moreover, we addressed this issue in the item "incomplete outcome data" of the 'Risk of bias' tool.

Assessment of heterogeneity

1. Clinical heterogeneity

We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. If such situations or participant groups arose, we would have fully discussed them.

2. Methodological heterogeneity

We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. If such methodological outliers arose, we would have fully discussed them.

3. Statistical heterogeneity

3.1. Visual inspection

We visually inspected graphs to investigate the possibility of statistical heterogeneity.

3.2. Employing the I^2 statistic

We investigated heterogeneity between studies by considering the I^2 statistic alongside the χ^2 'P' value. The I^2 statistic provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I^2 statistic depends on the magnitude and direction of effects and the strength of evidence for heterogeneity (e.g. a 'P' value from the χ^2 test, or a CI for the I^2 statistic). We considered an I^2 statistic estimate of 50% or greater accompanied by a statistically significant χ^2 statistic as evidence of substantial levels of heterogeneity (Deeks 2011). Had we found substantial levels of heterogeneity in the primary outcome, we would have explored reasons for heterogeneity (Subgroup analysis and investigation of heterogeneity).

Assessment of reporting biases

1. Protocol versus full study

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in the *Cochrane Handbook for Systemic Reviews of Interventions* (Sterne 2011). We tried to locate protocols of included randomised trials. If the protocol had been available, we would have compared outcomes in the protocol and in the published report. If the protocol was not available, we compared outcomes listed in the methods section of the trial report with actually reported results.

2. Funnel plot

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These are described in Chapter 10 of the *Cochrane Handbook for*

Systemic Reviews of Interventions (Sterne 2011). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We would not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In future updates, where funnel plots are possible, we will seek statistical advice in their interpretation.

Data synthesis

We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies, even if there is no statistically significant heterogeneity. However, there is a disadvantage to the random-effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose to use random-effects models in data analyses.

Subgroup analysis and investigation of heterogeneity

1. Subgroup analyses

1.1. Primary outcomes

No subgroup analysis was anticipated.

1.2. Clinical state, stage or problem

We proposed to undertake this review and provide an overview of the effects of chlorpromazine versus metiapine for people with schizophrenia in general. In addition, we planned to report data on subgroups of people in the same clinical state, stage and with similar problems if the data were available.

2. Investigation of heterogeneity

We intended to report high inconsistency. First, we would have investigated whether data had been entered correctly. Second, if data were correct, we would have visually inspected the graph and removed outlying studies to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present such data. If not, we would not pool these data but discuss them instead. We knew of no supporting research for this 10% cut off but are investigating the use of prediction intervals as an alternative to this unsatisfactory state.

If unanticipated clinical or methodological heterogeneity were obvious, we would have simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these.

Sensitivity analysis

We did not include any sensitivity analyses in this review as most outcomes were reported by only one study. If we had, we would have followed the methods below

1. Implication of randomisation

Where included studies implied randomisation, we would have included them in a sensitivity analysis. For the primary outcomes,

we would have included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have used all relevant data from these studies.

2. Assumptions for lost binary data

Where assumptions had to be made regarding people lost to follow-up (see [Dealing with missing data](#)), we would have compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. If there was a substantial difference, we would have reported results and discussed them but continued to employ our assumption.

Where assumptions had to be made regarding missing SDs data (see [Dealing with missing data](#)), we would have compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. We would have undertaken a sensitivity analysis to test how prone results were to change when completer-only data were compared to the imputed data using the above assumption. If there was a substantial difference, we would have reported results and discussed them but continued to employ our assumption.

3. Risk of bias

We would have analysed the effects of excluding trials that were judged at high risk of bias across one or more of the domains of randomisation (see [Assessment of risk of bias in included studies](#)). If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we would have included data from these trials in the analysis.

4. Imputed values

We also would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials.

If there were substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but presented them separately.

5. Fixed and random effects

We synthesised all data using a random-effects model; however, we also synthesised data for the primary outcome using a fixed-effect model to evaluate whether this altered the significance of the results. If results had been different, we would have discussed this issue.

RESULTS

Description of studies

See [Characteristics of included studies](#) table.

Results of the search

Details of the search results are illustrated in the PRISMA table ([Figure 3](#)).

Figure 3. Study flow diagram.

Initially we identified four records that seemed relevant to this review. After checking for duplicates, we inspected full text of all remaining reports. We then grouped these into 'studies' where two reports referred to the same trial. Of these, after scrutiny, we included four publications reporting three studies and did not exclude any.

Included studies

We included three studies ([Kramer 1975](#); [Simpson 1973](#); [Steinbook 1975](#)).

1. Methods

Two included studies were parallel ([Kramer 1975](#); [Steinbook 1975](#)) and one was cross-over ([Simpson 1973](#)). All studies were randomised.

2. Length of trials

All studies were short term. [Kramer 1975](#) was four weeks and [Steinbook 1975](#) was six weeks. [Simpson 1973](#) was the longest with a total duration of 28 weeks, 12 weeks up to the point of cross-over.

3. Participants

All studies stated that their participants were adults (aged 18 to 60 years) with schizophrenia. Only [Kramer 1975](#) described the diagnostic criteria using clinical diagnosis of schizophrenia of recent onset or exacerbation and an elevated combined score of 12 on five selected items of the BPRS. All participants were inpatients, participants in [Kramer 1975](#) were newly admitted.

4. Setting

All studies were single site and conducted in hospital.

5. Study size

Study size was small ranging from 11 ([Simpson 1973](#)) to 90 ([Kramer 1975](#)) participants per trial. A total of 161 participants were randomised.

6. Intervention

6.1. Chlorpromazine

The doses of chlorpromazine ranged from 50 mg/day to 1200 mg/day with a mean of 427 mg/day ([Kramer 1975](#)); 150 mg/day to 900 mg/day with a mean of 627 mg/day ([Steinbook 1975](#)); and 100 mg/day to 600 mg/day (mean dose was not provided) ([Simpson 1973](#)).

6.2. Metiapine

The doses of metiapine in included studies ranged from 25 mg/day to 600 mg/day (mean dose 219 mg/day) ([Kramer 1975](#)); 75 mg/day to 450 mg/day (mean dose 287 mg/day) ([Steinbook 1975](#)); and 100 mg/day to 600 mg/day (mean dose was not provided) ([Simpson 1973](#)).

6.3. Combination of butabarbital and atropine

[Kramer 1975](#) had a third treatment arm where participants were randomised to receive a combination of butabarbital and atropine. We did not use these data for this review.

7. Outcomes

The studies reported the following outcomes: global state, adverse effects, leaving the study early and service utilisation. None of the included studies reported data for mental state, relapse, quality of life, levels of satisfaction, service use, behaviour or cost of care. Most outcomes reported were dichotomous. [Kramer 1975](#) reported continuous outcomes that could be dichotomised.

7.1. Outcome scales

The following scale provided continuous data for the analysis.

7.1.1. Global state

i. Clinical Global Impression (CGI) ([Guy 1976](#))

The CGI scale enables clinicians to quantify severity of illness and overall clinical improvement. In this 7-point scoring system, lower scores indicated decreased severity or better recovery (used by [Kramer 1975](#); [Steinbook 1975](#)).

ii. Nurse's Observation Scale for Inpatient Evaluation (NOSIE) ([Honigfeld 1965](#))

The NOSIE is an 80-item scale with items rated on a 5-point scale from 0 (not present) to 4 (always present). Ratings are based on behaviour over the previous three days. The seven headings are social competence, social interest, personal neatness, cooperation, irritability, manifest psychosis and psychotic depression. The total score ranges from 0 to 320 with high scores indicating a poor outcome.

Excluded studies

We have no excluded studies in this review.

Risk of bias in included studies

See [Figure 4](#) and [Figure 5](#).

Figure 4. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 5. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Kramer 1975	+	?	+	?	+	?	?
Simpson 1973	+	?	+	+	+	?	?
Steinbook 1975	+	?	+	?	+	?	?

Allocation

All studies described the methods used for random sequence generation and rated as low risk. One study reported that participants were randomly assigned in blocks of six (Kramer 1975), and one study reported that participants were randomised using table of random numbers (Simpson 1973). Steinbook 1975 reported participants were randomly allocated to groups and the resulting groups did not differ significantly with respect to age, race, education or number of previous hospitalisations. However, none of the studies described allocation concealment and we rated all three as unclear risk for selection bias.

Blinding

All studies reported as double-blind studies and rated as low risk for performance bias. However, only one study stated that in addition to blinding of treatment, the physicians or nurses conducting outcome assessment were also blind (Simpson 1973). Kramer 1975

and Steinbook 1975 did not provide this information and we rated these two studies as unclear risk for detection bias.

Incomplete outcome data

All studies were at low risk of bias for incomplete outcome data as all studies addressed missing data issues clearly.

Selective reporting

All studies had unclear risks of bias for selective reporting as, although all expected outcomes were reported in the studies, some means and SDs were not reported.

Other potential sources of bias

Kramer 1975 and Simpson 1973 had an unclear risk of other bias as the treatments used were supplied by the pharmaceutical industry but declared no source of funding. Steinbook 1975 did not report source of funding, again we rated 'other bias' for this study to be unclear.

Effects of interventions

See: [Summary of findings for the main comparison Chlorpromazine versus metiapine for schizophrenia](#)

Studies relevant to this review fall into a single comparison. We were able to extract numerical data from three randomised studies.

1. COMPARISON 1: CHLORPROMAZINE versus METIAPINE (all data short term)

1.1 Global state: 1a. Clinically important improvement (CGI, high=poor)

Two trials with a total of 120 participants reported data. We did not find evidence of clear difference between chlorpromazine and metiapine (RR 1.11 95% CI 0.84 to 1.47, [Analysis 1.1](#)).

1.2 Global state: 2a. Overall: remaining symptomatic

One trial involving ten participants reported data for numbers of participants remaining symptomatic throughout the trial. We did not find evidence that chlorpromazine was clearly different in its effects compared with metiapine (RD 0.00 95% CI -0.31 to 0.31, [Analysis 1.2](#)).

1.3 Global state: 3. Overall: mean endpoint score (NOSIE, high=poor)

One trial, with a total of 60 participants reported data. We did not find evidence of a clear difference between chlorpromazine and metiapine (MD 0.20 95% CI -3.49 to 3.89, [Analysis 1.3](#)).

1.4 Adverse effects: 1. General: "severe reactions"

Three studies involving 140 participants reported data. We did not find evidence of a clear difference between chlorpromazine and metiapine for numbers of participants with "severe reactions" (RR 0.79 95% CI 0.41 to 1.49, [Analysis 1.4](#)).

1.6 Adverse effects: 2a. Specific: central nervous system - drowsiness

A single study, with a total of 60 participants reported data. We did not find evidence of a clear difference between chlorpromazine and metiapine (RR 1.00 95% CI 0.15 to 6.64, [Analysis 1.5](#)).

1.7 Adverse effects: 2b. Specific: hepatic - abnormal liver function test

Two studies, with a total of 120 participants, reported data. There was not a clear difference between chlorpromazine and metiapine (RR 1.35 95% CI 0.17 to 10.75, [Analysis 1.6](#)).

1.8 Adverse effects: 2c. Specific: movement disorders

We did not find evidence of a clear difference between chlorpromazine and metiapine for akathisia (1 RCT, n=60, RR 1.00 95% CI 0.32 to 3.10), dystonic symptoms (1 RCT, n=60, RR 5.00 95% CI 0.25 to 99.95), parkinsonism (2 RCTs, n=70, RR 0.97 95% CI 0.46 to 2.03), rigidity (1 RCT, n=60, RR 0.63 95% CI 0.23 to 1.69), tremor (1 RCT, n=60, RR 0.33 95% CI 0.01 to 7.87) or 'use of anti-parkinson or other remedial medication' (1 RCT, n=10, RR 1.22 95% CI 0.73 to 2.06, [Analysis 1.7](#)).

1.9 Adverse effects: 2d. Specific: others

1.9.1 Autonomic - blurred vision

A single trial, with a total of 60 participants provided data. We did not find evidence of a clear difference between chlorpromazine and metiapine (RR 5.00 95% CI 0.25 to 99.95, [Analysis 1.8](#)).

1.9.2 Cardiovascular (heart) problem

Three trials, which included a total of 130 participants reported data. we did not find evidence of a clear difference between chlorpromazine and metiapine (RR 0.52 95% CI 0.09 to 3.08). This subgroup had important levels of heterogeneity ($\chi^2=2.88$; df=1.0; $P=0.09$; $I^2=65\%$, [Analysis 1.8](#)).

1.9.3 Ophthalmological - "eye changes"

One trial, with a total of ten participants reported data. No one had eye changes in either group ([Analysis 1.8](#)).

1.10 Leaving the study

Two trials, with a total of 70 participants reported data. We did not find evidence of a clear difference between chlorpromazine and metiapine in this comparison (RR 0.33 95% CI 0.01 to 7.87, [Analysis 1.9](#)).

1.11 Service utilisation: staying in hospital

A single study, with a total of 60 participants reported data. There was not a clear difference between chlorpromazine and metiapine (RR 1.05 95% CI 0.74 to 1.48, [Analysis 1.10](#)).

DISCUSSION

Summary of main results

The summary below indicates the outcomes selected for the [Summary of findings for the main comparison](#), and highlights other important findings of this review for evidence-based decision making.

1. Global state

By analysing the results of two trials (total n = 120), there was no indication of a difference between metiapine and the much better established chlorpromazine for improvement of global state. With short- and medium-term data for chlorpromazine versus placebo, around one third of people do improve over and above that improvement that may come even with placebo ([Adams 2014](#)). If that held true for metiapine then that would be most important, but results cannot be regarded as conclusive without further trials.

2. Mental state

All data in this review were very limited, but there were no usable data on mental state that could be extracted from the trials. This is not that unusual and certainly not particular to this comparison but the case for retaining metiapine as a useful drug must be damaged by poor reporting or not recording such important outcomes in trials.

3. Adverse effects

Acute movement disorders, parkinsonism, tremor and rigidity are among well-recognised adverse effects reported by people using chlorpromazine ([Adams 2014](#); [Tardy 2014a](#)). As a low-

potency antipsychotic drug, chlorpromazine produces movement disorders, dizziness, sedation and weight gain (Tardy 2014b). The very few studies in this review supported these findings. Our results did not illustrate any clear difference between chlorpromazine and metiapine - although more data are needed to be sure of this.

4. Leaving the study early

There is evidence that using chlorpromazine leads to more people staying in the study - perhaps through a mechanism of decreasing distressing symptoms and increasing the person's concordance with treatment (Adams 2014). In our review, only two studies specifically reported the number of people who left the study early (total $n = 70$) and there was no clear difference between groups - only one person left. Larger numbers over longer periods of time would have been helpful but, on this low evidence, there was no indication that metiapine is any more unacceptable than chlorpromazine.

5. Service use

One study found no difference between groups for numbers able to be discharged from hospital at the end of the trial. This is a useful and widely understandable outcome. Data were few and of poor quality so confidence in this finding was low.

6. Satisfaction of participant or care provider with treatment/behaviour/cost of care

Because of no data or lack of usable data we can only highlight that we do not have any quantitative data from trials. There are many large gaps in our knowledge to compare metiapine versus chlorpromazine. These gaps could be easily rectified should a trial be designed and conducted.

Overall completeness and applicability of evidence

1. Completeness

Of the three included studies, all reported some data for the primary outcome of global state but this amounted to poor-quality data on 120 people in the short term. There were no long-term data. There were no usable data for mental state, a key outcome of this review. Similarly, often only one or two studies reported on secondary outcomes and all trials were small so all data were incomplete or entirely absent. All included studies were characterised by small sample sizes (fewer than 100 participants). Almost 1000 participants are required to be included in psychiatric meta-analyses for the results to be sound and robust (Trikalinos 2004). This review included 161 participants overall (120 for the primary outcome), so all analyses were underpowered. There were no data on behaviour, quality of life, level of satisfaction with care and cost of care. It seems likely that the data will remain incomplete. New larger well-designed studies comparing chlorpromazine with metiapine are desirable but probably unlikely. This state of incompleteness probably represents the most complete data set we are likely to get.

2. Applicability

Included studies were from the 1970s. In these studies, participants were diagnosed by less rigorous criteria than tends to be seen in modern trials but this, conversely, could make them more applicable to everyday care rather than less. Clinicians tend not to use very rigid rigorous criteria for diagnosis of schizophrenia in clinical care. Misdiagnoses are made but most people with a

clinical diagnosis of schizophrenia probably do really have the illness. These old trials may be more like clinical care than would be seen nowadays. All included studies were conducted in hospitals. Therefore, applicability towards people with schizophrenia in the community must be made by caution. All participants were inpatients, which could have contributed to the very low attrition rate that probably would have been different should the studies have been conducted in the community.

Quality of the evidence

The quality of the current evidence was low to very low based on GRADE (Schünemann 2011). Three studies reported the method of randomisation and only two reported the method of allocation concealment. All studies were reported as double blind, but only one stated that the assessor was blinded to which drug participants were receiving. Studies often reported no usable data on important outcomes as they solely reported statistical measures of probability (P value) or means without any SDs or SEs. Inconsistency, imprecision and publication bias of one included study were also problematic. This led to us grading the evidence as low quality in the 'Summary of findings' table.

Potential biases in the review process

The search was based on Cochrane Schizophrenia Trials Register. There may be some unpublished trials that we were unaware of. At the time this review's trials were published, there was pharmaceutical industry interest in the findings and this could have led to publication or reporting bias.

Agreements and disagreements with other studies or reviews

We are unaware of any other systematic reviews on the efficacy of chlorpromazine versus metiapine for schizophrenia.

AUTHORS' CONCLUSIONS

Implications for practice

1. For people with schizophrenia

This review should not give anyone confidence that metiapine is a real alternative to the much better researched chlorpromazine - but it could be. Schizophrenia is such a difficult illness that all useful or potentially useful drugs should be properly considered. At present, evidence for metiapine is too limited to encourage wide use. More studies are really needed and it would be understandable, if offered, metiapine, that people with schizophrenia would encourage and even help researchers generate better evidence than currently exists.

2. For clinicians

We found no differences in the efficacy of chlorpromazine versus metiapine for schizophrenia. This is intriguing as chlorpromazine is an effective drug and, even now, clinicians have too few drugs to use to treat schizophrenia. Probably the use of metiapine should be undertaken within the context of research.

3. For policy makers

There is no evidence to encourage adoption of metiapine for treatment of schizophrenia but much evidence to promote research into its effects.

Implications for research

1. General

Mostly the included studies were conducted in the 1970s, so all were 'pre'-CONSORT (Moher 2001), and we judge quality of conduct and reporting by standards of today. However, if standards of today had been applied, we may know a little more about metiapine. Currently, this review provides the best available evidence on the efficacy of chlorpromazine versus metiapine for people with schizophrenia.

2. Specific

2.1. Reviews

Because the search was so specific we excluded no trials. These usually suggest other reviews that could be undertaken. In this review, we have only one unused randomised comparison within Kramer 1975 (barbiturates plus atropine) which could conceivably be used in other reviews.

2.2. Trials

This review found that trials comparing chlorpromazine with the much lesser known metiapine are possible and provide enough

results to suggest that metiapine could be a useful - and we think largely forgotten - antipsychotic drug. We are currently unaware of any reasons to not undertake more trials on this question. We also know that design of such trials does take time and great dedication but have given this some thought and provided a draft of what such a trial might begin to look like (Table 2).

ACKNOWLEDGEMENTS

The Cochrane Schizophrenia Group Editorial Base in Nottingham, UK produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.

The search term was developed by the Trials Search Co-ordinator of the Cochrane Schizophrenia Group and the contact author of this review.

Parts of this review were generated using RevMan HAL v 4.0 (RevMan5).

We would also like to thank Chak Fa Ma, Dan Bressington, Maolin Du and Eyal Dahan for peer reviewing this version of the review.

REFERENCES

References to studies included in this review

Kramer 1975 {published data only}

Kramer M, Roth T, Goldstein S, Ryan MS, Blackwell B. A double-blind evaluation of metiapine in hospitalized acute schizophrenics. *Current Therapeutic Research* 1975;**18**(6):839-48.

Simpson 1973 {published data only}

Simpson G. Metiapine and chlorpromazine. *Bulletin* 1973;**9**:69-71.

Simpson G, Maher EJ, Herkert E, Lee JH. A controlled comparison of metiapine and chlorpromazine in chronic schizophrenia. *Journal of Clinical Pharmacology* 1973;**13**(10):408-15.

Steinbook 1975 {published data only}

Steinbook RM, Goldstein BJ, Brauzer B, Jacobson AF, Moreno S. Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients. *Journal of Clinical Pharmacology* 1975;**15**(10):700-4.

Additional references

Adams 2014

Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. *Cochrane Database of Systematic Reviews* 2014, Issue 1. [DOI: [10.1002/14651858.CD000284.pub3](https://doi.org/10.1002/14651858.CD000284.pub3)]

Ahmed 2010

Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2010, Issue 4. [DOI: [10.1002/14651858.CD007445.pub2](https://doi.org/10.1002/14651858.CD007445.pub2)]

Almerie 2007

Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. *Cochrane Database of Systematic Reviews* 2007, Issue 1. [DOI: [10.1002/14651858.CD006329](https://doi.org/10.1002/14651858.CD006329)]

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**(7066):1200.

Bazrafshan 2015

Bazrafshan A, Zare M, Okhovati M, Shamsi Meimandi M. Acetophenazine versus chlorpromazine for schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 4. [DOI: [10.1002/14651858.CD011662](https://doi.org/10.1002/14651858.CD011662)]

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**:600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problematique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacité]. *Thérapie* 1999;**54**(4):405-11. [PUBMED: 10667106]

Carpenter 1994

Carpenter WT Jr, Buchanan RW. Schizophrenia. *New England Journal of Medicine* 1994;**330**(10):681-90. [PUBMED: 8107719]

Crow 1980

Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. *British Journal of Psychiatry* 1980;**137**:383-6. [PUBMED: 7448479]

Deeks 2000

Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Dickenson 2013

Dickenson R, Fenton M. Zotepine versus placebo for schizophrenia. *Cochrane Database of Systematic Reviews* 2013, Issue 7. [DOI: [10.1002/14651858.CD010644](https://doi.org/10.1002/14651858.CD010644)]

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

Dold 2012

Dold M, Li C, Tardy M, Leucht S. Haloperidol versus first generation antipsychotics for schizophrenia. *Cochrane Database of Systematic Reviews* 2012, Issue 5. [DOI: [10.1002/14651858.CD009831](https://doi.org/10.1002/14651858.CD009831)]

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**:2971-80.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629-34.

Elbourne 2002

Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-

over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9.

Elis 2013

Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. *Clinical Psychology Review* 2013;**33**:912-28. [DOI: [10.1016/j.cpr.2013.07.001](https://doi.org/10.1016/j.cpr.2013.07.001)]

Eslami 2015

Eslami Shahrbabaki M, Sharafkhani R, Dehnavieh R, Vali L. Chlorpromazine versus piperacetazine for schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 6. [DOI: [10.1002/14651858.CD011709](https://doi.org/10.1002/14651858.CD011709)]

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *Journal of Clinical Epidemiology* 2006;**59**(7):7-10.

Gallant 1970

Gallant DM, Bishop MP, Guerrero-Figueroa R. Metiapine: a new antipsychotic agent. *Current Therapeutic Research* 1970;**12**(12):794-7.

Gibson 1973

Gibson JP, Rohovsky MW, Newberne JW, Larson EJ. Toxicity studies with metiapine. *Toxicology and Applied Pharmacology* 1973;**25**(2):220-9.

Grozier 1973

Grozier L. The third revolution in psychiatry: fluphenazine decanoate. In: Ayd FJ editor(s). *The Future of Pharmacotherapy: Drug Delivery System*. Baltimore: International Drug Therapy Newsletter, 1973:97.

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**:876-83.

Guy 1976

Guy U. *Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology*. National Institute of Mental Health 1976.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2011a

Higgins JPT, Green S. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Higgins 2011b

Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Higgins 2011c

Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Honigfeld 1965

Honigfeld G, Klett CJ. The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia. *Journal of Clinical Psychology* 1965;**21**:65-71.

Hutton 2009

Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. *British Journal of Haematology* 2009;**146**(1):27-30.

Kay 1986

Kay SR, Opler LA, Fiszbein A. *Positive and Negative Syndrome Scale (PANSS) Manual*. North Tonawanda, NY: Multi-Health Systems, 1986.

Ketteler 1970

Ketteler HJ, Kuhn WL. Metiapine: neuroleptic and peripheral autonomic attributes. *Federation of American Societies for Experimental Biology* 1970;**29**:620.

Khalili 2015

Khalili N, Vahedian M, Nikvarz N, Piri M. Chlorpromazine versus penfluridol for schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 8. [DOI: [10.1002/14651858.CD011831](https://doi.org/10.1002/14651858.CD011831)]

Leon 2006

Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. *Biological Psychiatry* 2006;**59**(11):1001-5. [PubMed: 16905632]

Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. *British Journal of Psychiatry* 2005;**187**:366-71. [PubMed: 16199797]

Leucht 2005b

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. *Schizophrenia Research* 2005;**79**(2-3):231-8. [PubMed: 15982856]

Leucht 2008

Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia.

Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: [10.1002/14651858.CD004278.pub2](https://doi.org/10.1002/14651858.CD004278.pub2)]

Liu 2009

Liu X, De Han S. Chlorpromazine dose for people with schizophrenia. *Cochrane Database of Systematic Reviews* 2009, Issue 2. [DOI: [10.1002/14651858.CD007778](https://doi.org/10.1002/14651858.CD007778)]

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249-52.

Mazhari 2015

Mazhari S, Esmailian S, Shahesmaeili A, Goughari AS, Bazrafshan A, Zare M. Chlorpromazine versus clotiapine for schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 8. [DOI: [10.1002/14651858.CD011810](https://doi.org/10.1002/14651858.CD011810)]

Moher 2001

Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *Lancet* 2001;**357**(9263):1191-4.

Overall 1962

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychological Reports* 1962;**10**:799-812.

RevMan 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Saha 2013

Saha KB, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. *Cochrane Database of Systematic Reviews* 2013, Issue 7. [DOI: [10.1002/14651858.CD010631](https://doi.org/10.1002/14651858.CD010631)]

Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Sterne 2011

Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Intervention*. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Tardy 2011

Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia. *Cochrane Database of Systematic Reviews* 2011, Issue 8. [DOI: [10.1002/14651858.CD009227](https://doi.org/10.1002/14651858.CD009227)]

Tardy 2014a

Tardy M, Dold M, Engel RR, Leucht S. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database of Systematic Reviews* 2014, Issue 9. [DOI: [10.1002/14651858.CD009227.pub2](https://doi.org/10.1002/14651858.CD009227.pub2)]

Tardy 2014b

Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database of Systematic Reviews* 2014, Issue 7. [DOI: [10.1002/14651858.CD009268.pub2](https://doi.org/10.1002/14651858.CD009268.pub2)]

Trikalinos 2004

Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. Effect sizes in cumulative meta-analyses of mental health randomised trials evolved over time. *Journal of Clinical Epidemiology* 2004;**57**(11):1124-30.

Ukoununne 1999

Ukoununne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):1-75.

WHO 2001

World Health Organization. World Health Report. Geneva: World Health Organization, 2001.

WHO 2011

World Health Organization. WHO Model List of Essential Medicines. 30th Edition. Vol. 17, Geneva: World Health Organization, 2011.

Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. *Psychiatric Bulletin* 2009;**33**(7):254-7.

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Kramer 1975

Methods	Allocation: randomly assigned by block - no further description.
	Blindness: double - identical capsules.

Kramer 1975 (Continued)

Duration: 4 weeks.

Design: parallel.

Country: USA.

Setting: hospital.

Participants	<p>Diagnosis: acute schizophrenia (presence of clinical symptoms according to BPRS).</p> <p>n = 90.</p> <p>Age: range 18 to 54 years, mean ~ 33 years.</p> <p>Sex: 70 men, 20 women.</p> <p>History: newly admitted to hospital.</p> <p>Excluded: history of brain, cardiovascular, hepatic or renal disorders; history of alcoholism or drug addiction; mental retardation; history or clinical evidence of glaucoma.</p>
Interventions	<p>1. Metiapine: range 25 mg/day to 600 mg/day, mean 219 mg/day. n = 30.*</p> <p>2. Chlorpromazine: range 50 mg/day to 1200 mg/day, mean 427 mg/day. n = 30.</p> <p>3. Combination of butabarbital + atropine: between butabarbital sodium 225 mg/day + atropine sulphate 0.26 mg/day and butabarbital sodium 180 mg/day + atropine sulphate 2.04 mg/day. Mean butabarbital sodium 78 mg/day + atropine sulphate 1.17 mg/day. n = 30.</p>
Outcomes	<p>Global state: clinical improvement (CGI), nurse's evaluation (change score NOSIE).</p> <p>Adverse effects: movement disorders, hepatic problems, 'severe reactions', cardiovascular problems.</p> <p>Leaving the study early.</p> <p>Unable to use:</p> <p>Mental state: BPRS (no SD).</p>
Notes	<p>* Only 5 of the metiapine participants, 1 of chlorpromazine participants and 1 of the butabarbital + atropine participants received maximal dosage.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "recently hospitalized schizophrenics who were randomized into three groups." "Patients were assigned in blocks of six, with two patients being assigned to each of the three groups."
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "a four-week double-blind study."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided.

Chlorpromazine versus metiapine for schizophrenia (Review)

Kramer 1975 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data were addressed in the study. Full-analysis-set, used to assess efficacy measures. All-participants-treated-set, used to assess safety measures.
Selective reporting (reporting bias)	Unclear risk	All expected outcomes reported, some means and SDs omitted.
Other bias	Unclear risk	Metiapine supplied by Merrell-National Laboratories. No source of funding reported.

Simpson 1973

Methods	Allocation: randomised - table of random numbers. Blindness: double. Duration: 28 weeks (4 weeks' placebo control, 8 weeks' intervention for each metiapine or chlorpromazine treatment, 4 weeks' placebo control, 8 weeks' cross-over period, and 4 weeks' drying out period). Setting: inpatient. Design: cross-over. Country: USA. Setting: hospital.
Participants	Diagnosis: schizophrenia (unclear means of diagnosis). n = 10*. Age: range 29 to 57 years. Sex: all men. History: "chronic", hospitalised > 1 year, majority "uncooperative", "withdrawn."
Interventions	1. Metiapine: capsule, range 100 mg/day to 600 mg/day. n = 5. 2. Chlorpromazine: capsule, range 100 mg/day to -600 mg/day. n = 5.
Outcomes	Global state: 'symptomatic', mean change score (GAS). Adverse effects: severe reactions, movement disorders (use of anti-parkinsonism medications "or other remedial medications," cardiovascular (ECG abnormalities), ophthalmological. Leaving the study early. Unable to use: Global state: CGI (no mean, n or SD, no data before cross-over). Mental state: BPRS (no mean, n or SD, no data before cross-over). Adverse effects: abnormal laboratory findings, central nervous system symptoms, autonomic system symptoms, "miscellaneous" of unclear meaning (percentages did not round to complete people), handwriting tests (no data before cross-over).

Simpson 1973 (Continued)

Notes * Only 10 participants entered treatment: "One patient did not meet symptom criteria at end of base-line period was dropped" - no more information.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Subjects were assigned to treatment on random number."
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The study was conducted under double blind condition."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "the patients and the physician or nurse conducting outcome assessment were unaware of the treatment each patient received."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Premature termination of treatment was not required by any subjects." Full-analysis-set, used to assess safety measures.
Selective reporting (reporting bias)	Unclear risk	All expected outcomes reported, some means and SDs omitted.
Other bias	Unclear risk	Metiapine supplied by Merrell-National Laboratories. Chlorpromazine supplied by SKF.

Steinbook 1975

Methods	Allocation: randomised. Blindness: double - identical capsules. Duration: 6 weeks. Design: parallel. Country: USA. Setting: hospital.
Participants	Diagnosis: acute schizophrenia (diagnosed by clinical symptoms). n = 60. Age: 21 to 60 years. Sex: 19 men, 41 women. History: newly admitted to hospital.
Interventions	1. Chlorpromazine: range 150 mg/day to 900 mg/day, mean 627 mg/day. n = 30.*

Chlorpromazine versus metiapine for schizophrenia (Review)

Steinbook 1975 (Continued)

2. Metiapine: range 75 mg/day to 450 mg/day, mean 287 mg/day. n = 30.*

Outcomes	<p>Global state: clinical improvement (CGI).</p> <p>Adverse effects: movement disorders, central nervous system, cardiovascular, 'severe reaction', hepatic.</p> <p>Service utilisation: staying in hospital.</p> <p>Unable to use:</p> <p>Mental state: BPRS (no SD).</p>
Notes	* 9 of metiapine participants and 11 of chlorpromazine participants were treated with maximum dosage.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Sixty patients were randomly assigned to metiapine or chlorpromazine."
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "in a double blind manner."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data or excluded participants from the study were reported. Full-analysis-set used to assess safety measures.
Selective reporting (reporting bias)	Unclear risk	All expected outcomes reported, some means and SDs omitted.
Other bias	Unclear risk	No source of funding reported.

BPRS: Brief Psychiatric Rating Scale;
 CGI: Clinical Global Impression;
 ECG: electrocardiogram;
 GAS: Global Assessment of Psychiatric Symptoms
 n: number of participants
 NOSIE: Nurse's Observation Scale for Inpatient Evaluation
 SD: standard deviation

DATA AND ANALYSES

Comparison 1. CHLORPROMAZINE versus METIAPINE (all data short term)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state: 1. Clinically important improvement (CGI, high = poor)	2	120	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.84, 1.47]
2 Global state: 2a. Overall: remaining symptomatic	1	10	Risk Difference (M-H, Random, 95% CI)	0.0 [-0.31, 0.31]
3 Global state: 2b. Overall: mean endpoint score (NOSIE, high = poor)	1	60	Mean Difference (IV, Random, 95% CI)	0.20 [-3.49, 3.89]
4 Adverse effects: 1. General: "severe reactions"	3	140	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.41, 1.49]
5 Adverse effects: 2a. Specific: central nervous system - drowsiness	1	60	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.15, 6.64]
6 Adverse effects: 2b. Specific: hepatic - abnormal liver function test	2	120	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.17, 10.75]
7 Adverse effects: 2c. Specific: movement disorders	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
7.1 Akathisia	1	60	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.32, 3.10]
7.2 Dystonic symptoms	1	60	Risk Ratio (M-H, Random, 95% CI)	5.0 [0.25, 99.95]
7.3 Parkinsonism	2	70	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.46, 2.03]
7.4 Rigidity	1	60	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.23, 1.69]
7.5 Tremor	1	60	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.01, 7.87]
7.6 Use of anti-parkinson or other remedial medication	1	10	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.73, 2.06]
8 Adverse effects: 2d. Specific: others	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
8.1 Autonomic - blurred vision	1	60	Risk Ratio (M-H, Random, 95% CI)	5.0 [0.25, 99.95]
8.2 Cardiovascular (heart) problem	3	130	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.09, 3.08]
8.3 Ophthalmological - "eye changes"	1	10	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
9 Leaving the study	2	70	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.01, 7.87]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10 Service utilisation: staying in hospital	1	60	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.74, 1.48]

Analysis 1.1. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 1 Global state: 1. Clinically important improvement (CGI, high = poor)).

Analysis 1.2. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 2 Global state: 2a. Overall: remaining symptomatic.

Analysis 1.3. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 3 Global state: 2b. Overall: mean endpoint score (NOSIE, high = poor).

Analysis 1.4. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 4 Adverse effects: 1. General: "severe reactions".

Analysis 1.5. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 5 Adverse effects: 2a. Specific: central nervous system - drowsiness.

Analysis 1.6. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 6 Adverse effects: 2b. Specific: hepatic - abnormal liver function test.

Analysis 1.7. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 7 Adverse effects: 2c. Specific: movement disorders.

Analysis 1.8. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 8 Adverse effects: 2d. Specific: others.

Analysis 1.9. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 9 Leaving the study.

Analysis 1.10. Comparison 1 CHLORPROMAZINE versus METIAPINE (all data short term), Outcome 10 Service utilisation: staying in hospital.

ADDITIONAL TABLES

Table 1. The Cochrane Reviews/protocols relevant to chlorpromazine for people with schizophrenia

Review title	Reference
Acetophenazine versus chlorpromazine for schizophrenia.	Bazrafshan 2015
Chlorpromazine dose for people with schizophrenia.	Liu 2009
Cessation of medication for people with schizophrenia already stable on chlorpromazine.	Almerie 2007
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.	Saha 2013
Chlorpromazine versus clotiapine for schizophrenia.	Mazhari 2015
Chlorpromazine versus metiapine for schizophrenia.	This review
Chlorpromazine versus penfluridol for schizophrenia.	Khalili 2015
Chlorpromazine versus piperacetazine for schizophrenia.	Eslami 2015
Chlorpromazine versus placebo for schizophrenia.	Adams 2014
Chlorpromazine for psychosis induced aggression or agitation.	Ahmed 2010
Haloperidol versus chlorpromazine for schizophrenia.	Leucht 2008

*

Table 2. Suggestions for design of future study

Methods	Allocation: randomised, with sequence generation and concealment of allocation clearly described. Blindness: double, tested. Duration: ≥ 12 months beyond end of intervention. Raters: independent.
----------------	--

Table 2. Suggestions for design of future study *(Continued)*

Participants	Diagnosis: people with schizophrenia - however diagnosed.* Age: any. Sex: both. History: any. n = 300.**
Interventions	1. Metiapine: about 200 mg/day. n = 150. 2. Chlorpromazine: about 400 mg/day. n = 150.
Outcomes	Global state - relapse, clinically important change. Mental state - general - clinically important change in mental state, mean change in negative symptoms. Adverse effects - incidence of serious adverse events/effects, clinically important extrapyramidal symptoms. Leaving the study early - for any reason. Cost of care. Service outcomes: admitted, number of admissions, length of hospitalisation, discharge, contacts with psychiatric services. Compliance with drugs. Economic evaluations: cost-effectiveness, cost-benefit.
Notes	* This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. ** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.

n: number of participants.

CONTRIBUTIONS OF AUTHORS

MZ: developed the protocol, selected trials, extracted and analysed data, and wrote the review.

AB: developed the protocol, selected trials, extracted and analysed data, and wrote the review.

DECLARATIONS OF INTEREST

MZ has no declarations of interest.

AB has no declarations of interest.

SOURCES OF SUPPORT

Internal sources

- Kerman University of Medical Sciences, Kerman, Iran.

Authors are students at this university

External sources

- None, Other.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We clarified which adverse effect was of interest - as the other reviews within this family of chlorpromazine comparisons have presented movement disorder data and due to chlorpromazine's known risk of causing movement disorders we felt this should be the adverse effect we presented for our review. We have also changed the wording of some outcomes from 'clinically significant' to 'clinically important'.

We have changed the text in 'why it is important to do this review' to clarify why it is important to compare these two antipsychotic drugs and so the text is similar to the other reviews in this series of chlorpromazine comparisons ([Table 1](#)).

We have added a sentence to the methods to clarify use of subscales

'(c) the instrument should be a global assessment of an area of functioning and not subscores which are not, in themselves, validated or shown to be reliable. However, there are exceptions, we will include subscores from mental state scales measuring positive and negative symptoms of schizophrenia'.

INDEX TERMS

Medical Subject Headings (MeSH)

Antipsychotic Agents [adverse effects] [*therapeutic use]; Chlorpromazine [adverse effects] [*therapeutic use]; Dibenzothiazepines [adverse effects] [*therapeutic use]; Parkinson Disease, Secondary [chemically induced]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Treatment Outcome

MeSH check words

Adult; Humans